Clinical Trials Update: Oct. 30, 2007
1816
(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:
736868
The world's biggest drug makers will  unveil plans on Thursday to publish more data about clinical  trials of their medicines in a bid to reassure patients about  their safety, according to industry sources.
273621
Pfizer Inc&#39;s experimental oral  biotechnology drug axitinib demonstrated substantial anti-tumor  activity in patients with advanced thyroid cancer in a small,  mid-stage clinical trial, according to data released at a major  cancer meeting on Saturday.
519863
The company faces a pivotal clinical trial.
281554
A U.S. advisory panel on Friday will  review data on an experimental drug that is injected into the  eye to stop vision loss in elderly patients at risk of going  blind.
275372
Drugmakers are working on experimental diabetes drugs using a novel mechanism to help flush excess blood sugar out of the body, according to results of small studies presented at a medical meeting on Sunday.
527274
roundup Plus: PMC-Sierra lowers forecast...WebSideStory cuts IPO to 4.4 million shares...BMC looks to simplify network operations.
335462
Description: A consortium of leading medical journals wants to prevent publication of clinical trial results that overemphasize positive data.
225429
2007 top science developments, tech flops, and vaporware...Szulik's parting words as Red Hat CEO...Sony Alpha A700 review...copyright tidbits...Toshiba 32nm deal with IBM
693379
questions over testing of a key HIV/AIDS drug before a US-backed roll-out of the treatment across the continent. Ingelheim to hide adverse effects of nevirapine when used to try to prevent mother-to-child HIV transmission.
93812
The results from the new clinical trial could increase the chances that the Food and Drug Administration will approve the drug for that use.
269165
A pivotal trial for lead drug, Ranexa, is nearing completion and results will be released in the first quarter of 2007.
367540
WEDNESDAY, Dec. 8 (HealthDayNews) -- Two separate studies offer some good news about two drugs for the treatment of Parkinson's disease.
743658
The U.S. Food and Drug Administration on Thursday ordered the review of preventative studies involving Pfizer Inc.'s painkillers Celebrex and Bextra, in light of recent evidence they may increase the risk of heart attack and stroke.
730173
TORONTO - Some of the world&#39;s most prestigious medical journals have banded together to force pharmaceutical and medical device companies to report the full results of clinical trials, both positive and negative.
390422
FRIDAY, Nov. 17 (HealthDay News) -- Just-released data from a trial that was stopped early in 2004 for safety reasons is re-igniting debate on the safety of two popular painkillers.
80442
The US Food and Drug Administration on Thursday ordered the review of preventative studies involving Pfizer Inc.&#39;s painkillers Celebrex and Bextra, in light of recent evidence they may increase the risk of heart attack and stroke.